Novel S1P1 Receptor Agonists - Part 2: From Bicyclo[3.1.0]hexane-Fused Thiophenes to Isobutyl Substituted Thiophenes
摘要:
Previously, we reported on the discovery of a novel series of bicyclo[3.1.0]hexane fused thiophene derivatives that serve as potent and selective S1P(1), receptor agonists. Here, we discuss our efforts to simplify the bicyclohexane fused thiophene head. In a first step the bicyclohexane moiety could be replaced by a simpler, less rigid cyclohexane ring without compromising the SIP receptor affinity profile of these novel compounds. In a second step, the thiophene head was simplified even further by replacing the cyclohexane ring with an isobutyl group attached either to position 4 or position S of the thiophene. These structurally much simpler headgroups again furnished potent and selective S1P(1) agonists (e.g., 87), which efficiently and dose dependently reduced the number of circulating lymphocytes upon oral administration to male Wistar rats. For several compounds discussed in this report lymphatic transport is an important route of absorption that may offer opportunities for a tissue targeted approach with minimal plasma exposure.
Thiophene derivatives as S1P1/EDGE1 receptor agonists
申请人:Bolli Martin
公开号:US20100048648A1
公开(公告)日:2010-02-25
The invention relates to novel thiophene derivatives, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents.
THIOPHENE DERIVATIVES AS S1P1/EDG1 RECEPTOR AGONISTS
申请人:Actelion Pharmaceuticals Ltd.
公开号:EP2069322A2
公开(公告)日:2009-06-17
US8133910B2
申请人:——
公开号:US8133910B2
公开(公告)日:2012-03-13
[EN] NOVEL THIOPHENE DERIVATIVES<br/>[FR] DÉRIVÉS INNOVANTS DU THIOPHÈNE
申请人:ACTELION PHARMACEUTICALS LTD
公开号:WO2008029306A2
公开(公告)日:2008-03-13
[EN] The invention relates to novel thiophene derivatives, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents. [FR] La présente invention concerne des dérivés innovants du thiophène, leur préparation et leur utilisation en tant que composés pharmaceutiquement actifs. Lesdits composés agissent en particulier en tant qu'agents immunomodulateurs.